Remarkable suppressive effect of consecutive low-dose cisplatin therapy on advanced ovarian clear cell adenocarcinoma.
Ovarian clear cell adenocarcinoma (OCCA) is known to be less responsive to cisplatin and most other anti-cancer drugs and to have a poorer prognosis than other ovarian cancers. We report a rare case of stage IIIc OCCA in a patient who has been treated postoperatively with cisplatin alone and continues to survive after 7.5 years. In this case, 25 mg/m2/day of cisplatin was administered for 5 consecutive days every 4 weeks. After remission, intermittent administration of cisplatin every 3 to 4 months was performed 8 times. This case suggests that induction and intermittent chemotherapy using consecutive low-dose cisplatin administration may be a useful treatment for OCCA.
Umesaki
N
N
Department of Obstetrics and Gynecology, Osaka City University Medical School, Abeno-ku, Osaka 545-8585, Japan.
Tanaka
T
T
Kawamura
N
N
Miyama
M
M
Ichimura
T
T
Ogita
S
S
D018262:Adenocarcinoma, Clear Cell / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology / Q000601:surgery; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002945:Cisplatin / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology / Q000601:surgery; D012074:Remission Induction
D000970:Antineoplastic Agents; D002945:Cisplatin